Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EECP (Enhanced External Counter Pulsation) benefits sustained at two years:

This article was originally published in Clinica

Executive Summary

Vasomedical says that data is now available to show that the reduction in angina achieved using its Enhanced External Counter Pulsation (EECP) therapy is sustained at two years. The results come from an analysis of 254 patients from an International EECP patient registry at the University of Pittsburgh Graduate School of Public Health in Pennsylvania. Before EECP therapy, 80% of patients had severe angina. This figure fell to 16% immediately following treatment and remained at this level for the next two years, says the Westbury, New York firm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT071144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel